22265-37-8

Usage

Uses

Used in Analytical Chemistry:
4-METHOXYBENZAMIDINE FOR FLUORESCENCE is used as a reagent for the determination of reducing carbohydrates and glycoproteins by postcolumn derivatization after high-performance liquid chromatography (HPLC). This application takes advantage of the compound's fluorescence properties to improve the detection and quantification of these biomolecules in complex samples.
Used in Research and Development:
In the field of research and development, 4-METHOXYBENZAMIDINE FOR FLUORESCENCE is employed as an improved alternative to benzamidine in various experimental setups. Its fluorescence characteristics allow for more accurate and sensitive detection of target molecules, leading to better understanding of biological processes and potential therapeutic applications.
Overall, 4-METHOXYBENZAMIDINE FOR FLUORESCENCE is a versatile compound with applications in both analytical chemistry and research, primarily due to its fluorescence properties that enhance the detection and analysis of specific molecules.

InChI:InChI=1/C8H10N2O/c9-4-2-5-10-7-8-3-1-6-11-8/h1,3,6,10H,2,5,7H2

Upstream product

• 3717-22-4 (Z)-para-methoxybenzaldehyde oxime 
• 70286-37-2 4-methoxy-benzaldehyde-(O-methyl-seqtrans-oxime ) 
• 874-90-8 4-methoxybenzonitrile 
• 930-69-8 sodium thiophenolate 
• 95911-61-8 3-Bromo-3-(4-methoxy-phenyl)-3H-diazirine 
• 7647-01-0 hydrogenchloride 
• 7753-12-0 2,4,6-tris-(4-methoxy-phenyl)-[1,3,5]triazine 
• 64-19-7 acetic acid 
• 7664-41-7 ammonia 
• 60-29-7 diethyl ether 
• 87861-04-9 (Z)-4-methoxybenzaldehyde O-methyloxime 
• 3717-21-3 (E)-4-methoxybenzaldoxime 
• 5373-87-5 4-methoxybenzamidoxime 
• 51721-68-7 4-methoxybenzamidine hydrochloride 

Downstream Products

• 103041-66-3 N-benzyl-N'-(4-methoxy-benzimidoyl)-thiourea 
• 92846-98-5 2-(4-methoxy-phenyl)-5-nitroso-pyrimidine-4,6-diamine 
• 70552-21-5 2-(4-methoxy-phenyl)-5-thiophen-2-yl-1H-imidazole 
• 475995-39-2 4-amino-2-(p-anisyl)-6-(2,4-dichlorophenyl)-pyrimidine-5-carbonitrile 
• 5466-70-6 2-(4-methoxy-phenyl)-7⁽⁹⁾H-purin-6-ylamine 
• 874120-06-6 methyl 4-(4-chloro-2-fluorophenyl)-6-methyl-2-[4-(methyloxy)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 

Relevant academic research and scientific papers

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

Nortopsentin alkaloid derivatives and preparation thereof, and application of nortopsentin alkaloid derivatives to prevention and treatment of diseases and insect pests

The invention relates to nortopsentin alkaloid derivatives I and preparation thereof, and application of the nortopsentin alkaloid derivatives I to resisting of plant viruses and pathogens and killingof insects. The nortopsentin alkaloid derivatives I in

Silver-catalyzed [3+2+1] annulation of aryl amidines with benzyl isocyanide

A silver-catalyzed [3+2+1] annulation of amidines with benzyl isocyanide toward 2,4-diaryl-1,3,5-triazines was developed. A variety of symmetrical and unsymmetrical products were obtained in moderate to good yields. This work also features an oxidant-free approach to 2,4-disubstituted triazines.

Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: Consequences for the prodrug concept "amidoximes instead of amidines"

The mitochondrial amidoxime reducing component (mARC) activates amidoxime prodrugs by reduction to the corresponding amidine drugs. This study analyzes relationships between the chemical structure of the prodrug and its metabolic activation and compares its enzyme-mediated vs. electrochemical reduction. The enzyme kinetic parameters KM and Vmax for the N-reduction of ten para-substituted derivatives of the model compound benzamidoxime were determined by incubation with recombinant proteins and subcellular fractions from pig liver followed by quantification of the metabolites by HPLC. A clear influence of the substituents at position 4 on the chemical properties of the amidoxime function was confirmed by correlation analyses of 1H NMR chemical shifts and the redox potentials of the 4-substituted benzamidoximes with Hammett's σ. However, no clear relationship between the kinetic parameters for the enzymatic reduction and Hammett's σ or the lipophilicity could be found. It is thus concluded that these properties as well as the redox potential of the amidoxime can be largely ignored during the development of new amidoxime prodrugs, at least regarding prodrug activation.

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION

Compounds and methods are provided for enhancing or boosting the transfection rate or efficiency of mammalian cells by foreign DNA, such as bacterial plasmid DNA. Compounds, including natural products and inventive synthetic compounds can increase the effectiveness of uptake and incorporation of foreign DNA by mammalian cells, such as human cells, by suppression of DNA cytosine deamination, which is believed to be a mechanism by which these cells eliminate foreign DNA. Inhibition of the cytosine deaminase enzymes by compounds as described herein serves to provide more effective transfection of eukaryotic cells by plasmids including engineered gene sequences. Transfection can be used to study cellular processes, or to cure genetic diseases in human patients. The inventive materials and methods increase the efficiency and effectiveness of such transfection techniques.

Direct palladium(II)-catalyzed synthesis of arylamidines from aryltrifluoroborates

A fast and convenient synthesis of arylamidines starting from readily available potassium aryltrifluoroborates and cyanamides is reported. The coupling was achieved by Pd(II)-catalysis in a one step 20 min microwave protocol using Pd(O2CCF

Unsymmetrical 1α3-1,2,4,6-thiatriazinyls with aryl and trifluoromethyl substituents: Synthesis, crystal structures, EPR spectroscopy, and voltammetry

A general synthetic route to 3-trifluoromethyl-5-aryl-1α3- 1,2,4,6-thiatriazinyl radicals was developed. X-ray structures were obtained for all five neutral radicals and show that they exist in the solid state as cofacial dimers linked by S...S contacts. X-ray structures were also obtained for two of the precursor chlorothiatriazines along with several aryl N-imidoylamidines, p-methoxybenzamidine, and N-chlorosulfonyl- N,N'-benzamidine. Cyclic voltammetric studies were performed on the [R2C 2N3S]. radicals in CH3CN and CH 2Cl2 with [nBu4N][PF6] as the supporting electrolyte under vacuum conditions in an all-glass electrochemical cell. The results provide quasi-reversible formal potentials for the [R2C2N3S]-/0 process in the range of -0.61 to -0.47 V, irreversible peak potentials for the [R2C 2N3S]0/+ process from 0.59 to 0.91 V at lower concentrations, and the appearance of a second, reversible oxidation process from 0.69 to 0.94 V at higher concentrations (versus the Fc0/+ couple; Fc = ferrocene). This behavior was indicative of monomer-dimer equilibrium in solution, as ascertained from digital models of the voltammograms. There is a small but measurable trend in both the oxidation and reduction potentials with varying remote aryl substituents. EPR spectra were obtained for all five neutral radicals in CH2Cl2 solutions, which confirm the concentration of the unpaired electron density on the heterocyclic core. Trends were also seen in the hyperfine splitting constants aN with varying remote aryl substituents. Calculations were performed for all three oxidation states of the [R2C2N3S]-/./+ monomeric rings; the resulting theoretical redox energies correlate well with solution phase voltammetric data.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases

Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused on the optimization of dihydropyrimidine 2, which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.